Full-Time

Key Account Director

Posted on 1/17/2025

Tempus

Tempus

1,001-5,000 employees

AI-driven healthcare data analysis platform

Compensation Overview

$140k - $210kAnnually

+ Incentive Compensation + Restricted Stock Units

Expert

Company Historically Provides H1B Sponsorship

Remote in USA

Remote roles are open to individuals in unincorporated Los Angeles.

Category
Lab & Research
Life Sciences
Required Skills
Sales
Requirements
  • Minimum 10+ years in Business Development and Sales in the Life Sciences sector as lead account and relationship manager (Pharma / Biotech)
  • 5+ years working with companies who serviced Life Sciences companies in Research & Development and/or Real World Data
  • Proven experience delivering consistent sales results within Biopharma accounts
  • Entrepreneurial sales approach; thrives most in a high growth, rapidly evolving business environment
  • Expert in influencing internal and external stakeholders to quickly solve problems and deliver results
  • Deep understanding of the drug development life cycle and has relationships with key Biopharma industry stakeholders
  • Proven ability to navigate multi-faceted client organizations with repeated success
  • Exceptional account management and strategic selling skills, articulation of issues and an ability to navigate a wide range of stakeholders to solve problems
  • Proven track record of establishing credibility as a trusted advisor with clients
  • Experience negotiating and closing large and complex multi-year deals
  • Strong understanding of molecular data and artificial intelligence in drug discovery
  • Bachelor degree in a Science or Business discipline; Advanced degree (MBA, PhD or Healthcare certification) desired
Responsibilities
  • Proactively identify and close new sales opportunities within designated biopharma account(s).
  • Meet and exceed bookings goals while delivering on established strategic objectives for specific customer accounts
  • Develop a deep understanding of each account's unique needs and challenges and create a supporting Tempus strategy to address
  • Develop and drive global account strategy in coordination with our scientific and business operations teams
  • Build and maintain executive relationships & drive an executive engagement plan utilizing Tempus senior leadership team.
  • Become an expert in the partner’s strategy, pipeline and portfolio to proactively determine all areas that the Tempus platform could be leveraged for advancing innovation
  • Negotiate, secure and manage pull-through of contracts with assigned client accounts
  • Lead a cross functional team of Product Specialists, Alliance Managers, Translational Researchers and Commercial Operations to deliver value for our customers.
  • Partner with our customers to develop impactful case studies leveraging the Tempus platform to advance precision medicine
  • Contribute to the development of the Life Sciences portfolio by providing feedback to Leadership regarding client responses and suggestions; maintain a solution-oriented mindset
  • Track progress against defined strategic objectives and revenue goals; review progress/setbacks frequently with broader Account Team and Tempus Leadership
  • Travel approximately 40% of working time, domestically and internationally
Desired Qualifications
  • Advanced degree (MBA, PhD or Healthcare certification) desired

Tempus focuses on enhancing patient outcomes through the use of data and artificial intelligence in the healthcare sector. The company offers a platform that analyzes medical data, helping physicians make better treatment decisions by providing insights from medical images and identifying care gaps. For pharmaceutical and biotech companies, Tempus aids in drug development by discovering new targets and assessing treatment effectiveness. Patients benefit from personalized therapy options identified through the platform. Additionally, Tempus conducts research, particularly in cancer, and has developed tools like a pan-cancer organoid platform and a liquid biopsy assay for profiling tumor DNA. The company generates revenue by charging healthcare providers and companies for access to its platform and insights.

Company Size

1,001-5,000

Company Stage

IPO

Headquarters

Chicago, Illinois

Founded

2015

Simplify Jobs

Simplify's Take

What believers are saying

  • Tempus secured $560 million in debt financing to support growth and acquisitions.
  • Partnerships with Stemline and Artera expand Tempus' AI platform applications.
  • The launch of the Olivia app empowers patients with AI-driven health management.

What critics are saying

  • High debt levels may strain Tempus' financial stability if revenue targets aren't met.
  • Increased competition from AI healthcare platforms could erode Tempus' market share.
  • Regulatory challenges in AI and data privacy could impact Tempus' operations.

What makes Tempus unique

  • Tempus uses AI to provide personalized treatment insights for cancer patients.
  • Their platform integrates clinical and molecular data for precision medicine.
  • Tempus' AI-driven liquid biopsy assay enhances cancer detection and profiling.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Relocation Assistance

Company Equity

Performance Bonus

Growth & Insights and Company News

Headcount

6 month growth

0%

1 year growth

0%

2 year growth

1%
Business Wire
Feb 25th, 2025
Ares Management Upsizes Tempus Debt Facilities to $560 Million

Combined with $260 million of capital provided in 2022 and 2023, Ares Credit funds have provided Tempus a total debt package of approximately $560 million.

Pulse 2.0
Feb 24th, 2025
Tempus Secures $560M Debt Financing

Ares Management announced that Ares Credit funds provided $300 million in additional debt financing to Tempus AI, bringing the total debt package to $560 million. This financing supports Tempus' acquisition of Ambry Genetics, completed on February 3, 2025. Ares praised Tempus' growth strategy and AI-enabled solutions in medicine. Tempus' CFO, Jim Rogers, expressed appreciation for Ares' investment, which aids in enhancing healthcare technology and patient outcomes.

Hit Consultant
Feb 21st, 2025
Stemline Therapeutics To Deploy Tempus Next’S Ai-Enabled Care Pathway Intelligence Platform

Stemline Therapeutics to Deploy Tempus Next’s AI-Enabled Care Pathway Intelligence Platform. by Fred Pennic 02/21/2025 Leave a Comment. What You Should Know: – Tempus, a provider of AI-driven precision medicine, and Stemline Therapeutics, Inc. (“Stemline”), a wholly-owned subsidiary of the Menarini Group announced a new collaboration to improve the use of ESR1 testing in metastatic breast cancer (mBC). – The partnership will leverage Tempus’ Next platform, an AI-enabled care pathway intelligence tool, to help clinicians determine when ESR1 testing may be appropriate for their patients.Challenges in ESR1 TestingESR1 mutations are a critical factor in the progression of ER+/HER2- mBC, a common type of breast cancer. Up to 50% of patients with this type of cancer can develop ESR1 mutations after prior endocrine therapy. Recognizing this, the American Society of Clinical Oncology (ASCO) recommends ESR1 mutation testing at each disease progression. Tempus Next: Guiding Clinical DecisionsTempus’ Next platform will analyze clinical data from mBC patients and notify clinicians when ESR1 testing is missing at disease progression

ETF Daily News
Feb 15th, 2025
Apollon Wealth Management LLC Makes New $256,000 Investment in Tempus AI, Inc. (NASDAQ:TEM)

Apollon Wealth Management LLC makes new $256,000 Investment in Tempus AI, Inc. (NASDAQ:TEM).

Money Morning
Feb 14th, 2025
Nancy Pelosi's Favorite AI Stock Rising Again After 13% Surge

Tempus announced yesterday that it was collaborating with the nonprofit Institute for Follicular Lymphoma Innovation to develop treatment options for patients with the disease.

INACTIVE